Home » Newsletters » BioWorld Science

BioWorld Science

May 3, 2001

View Archived Issues

Preclinical models of ischemic stroke reveal neuroprotective activity of BMS-204352

Vertex to acquire Aurora Biosciences

Antisoma's Therex stimulates immune system to fight breast cancer

AVI BioPharma and Exelixis create antisense alliance

Reduced beta-amyloid peptide levels observed with statin drugs

Cialis demonstrates extended duration in clinical trials in ED

Testolactone treatment associated with beneficial effects in men with severe infertility

Oral endothelin receptor antagonist achieves primary endpoint in phase III trial for PAH

Pfizer identifies and characterizes potent and selective NHE-1 inhibitor

Ortho-McNeil, R.W. Johnson return rights to influenza drug candidate

Peptidomimetic FTase inhibitors may be useful in malaria in addition to cancer

Antithrombotic pentasaccharide assigned fast track review by FDA

Old drug holds promise in fatal childhood neurodegenerative disorder

Novartis Oncology announces Glivec name change in U.S.

Promising profile emerges from phase Ib trial of oral p38 kinase inhibitor; phase II planned

Axcan's Photofrin approved and launched in the U.K.

Oral iron chelator from Novartis and implications for the therapy of transfusional iron overload

Gilead seeks approval of tenofovir DF for treatment of HIV

FDA approves Xeloda for metastatic colorectal cancer

Kissei and Daiichi will codevelop and comarket BPH Rx in Japan

Protein enters preclinical development for acute thrombosis at Myriad Genetics

Ono's new glucopyranose derivatives have potential in HIV infection, etc.

Method of inhibiting PTP1B or T-cell protein tyrosine phosphatase described in patent

New antirhinoviral compounds in development at Biota

Inhibitors of protein prenyltransferases remain an R&D focus at Merck

Preparation and use of new VEGF receptor tyrosine kinase modulators reported in recent patent

New series synthesized at Arzneimittelwerk Dresden possess anticonvulsant, anxiolytic activity